IRVINE, Calif. and GUANGDONG PROVINCE, China, Feb. 24, 2011
/PRNewswire/ — Masimo (Nasdaq:
MASI) and Royal Fornia Electronic Device Co., Ltd. jointly
announce a worldwide technology licensing agreement to integrate
Masimo rainbow SET® Pulse CO-Oximetry™ technology into
Royal Fornia’s new generation of multiparameter patient
monitors—enabling advanced noninvasive blood constituent
measurements that help clinicians to detect and treat
life-threatening conditions earlier. Having recently received State
Food and Drug Administration (SFDA) approval for Masimo
rainbow® SET parameters in China, Royal Fornia establishes
itself as one of the first domestic Chinese medical device
manufacturers to commercially incorporate Masimo’s breakthrough
noninvasive blood constituent measurement capabilities.
Masimo rainbow® SET noninvasive and continuous
measurements—like total hemoglobin
(SpHb®), oxygen content (SpOC™), carboxyhemoglobin
(SpCO®), methemoglobin (SpMet®),
and Pleth Variability Index
(PVI®), in addition to the ‘gold-standard’
Measure-Through Motion and Low Perfusion performance of Masimo
SET® oxyhemoglobin (SpO2), perfusion index (PI), and pulse
rate (PR)—provide detailed physiological data that helps
clinicians to more rapidly assess patients and detect adverse
conditions much earlier. With rainbow® SET measurements,
the ability to noninvasively detect internal bleeding, carbon
monoxide poisoning, methemoglobinemia, fluid responsiveness, low
perfusion, desaturations, and abnormal pulse rates quickly, easily,
and continuously
‘/>”/>
SOURCE